Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer

In a prospective clinical initiative, we selected heavily pretreated head and neck carcinoma patients and assessed the clinical utility of a protein-based oncopanel for identification of potential targetable markers. Tumor samples of 45 patients were evaluated using a 12-marker immunohistochemistry...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2019-10, Vol.11 (14), p.1193-1203
Main Authors: Doescher, Johannes, Weissinger, Stephanie E, Schönsteiner, Stefan S, Lisson, Catharina, Bullinger, Lars, Barth, Thomas FE, Leithäuser, Frank, Mueller-Richter, Urs, Laban, Simon, Hoffmann, Thomas K, Möller, Peter, Lennerz, Jochen K, Schuler, Patrick J
Format: Article
Language:English
Subjects:
Cancer therapies
Clinical medicine
crizotinib
decision making
Epidermal growth factor
Epidermal growth factor receptors
Gene expression
Head & neck cancer
head and neck cancer
imatinib mesylate
Immunohistochemistry
Immunotherapy
Kinases
Lung cancer
Metastasis
Monoclonal antibodies
Next-generation sequencing
oncopanel
Patients
precision oncology
Proteins
Targeted cancer therapy
trastuzumab
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a prospective clinical initiative, we selected heavily pretreated head and neck carcinoma patients and assessed the clinical utility of a protein-based oncopanel for identification of potential targetable markers. Tumor samples of 45 patients were evaluated using a 12-marker immunohistochemistry panel. The primary end point was the prevalence of potentially actionable markers. At least one expressed marker in each case could be identified. We noted a high prevalence of EGFR (80%, 39/45) and MET (57.4%, 28/45). Three patients received oncopanel-based therapy with variable results. Despite the limited number of treated subjects, oncopanel analysis in end-stage head and neck cancer is operationally and technically feasible. Combination with targeted next generation sequencing might provide additional therapy options.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2019-0041